Fractional Anisotropy in the Posterior Limb of the Internal Capsule and Prognosis in Amyotrophic Lateral Sclerosis

Ricarda A. L. Menke, PhD; Ivy Abraham, BSc; Catherine S. Thiel; Nicola Filippini, DPhil; Steve Knight, BSc; Kevin Talbot, DPhil; Martin R. Turner, PhD

**Objective:** To explore the value of diffusion tensor imaging applied to those specific cerebral white matter tracts consistently involved pathologically in amyotrophic lateral sclerosis as a source of prognostic biomarkers.

**Design:** Baseline clinical assessment and 3-T diffusion tensor imaging, repeated after approximately 6 months. Tract-based spatial statistics were used to assess voxel-wise correlations of just the baseline diffusion tensor imaging indices with the progression rate (change in disability score/time interval) within the corticospinal tract and corpus callosum.

**Patients:** The study involved 21 patients with amyotrophic lateral sclerosis and 3 patients with primary lateral sclerosis.

**Results:** Correlation was observed between fractional anisotropy and progression rate for a region of the corticospinal tract spanning the posterior limb of the internal capsule, with a left hemisphere emphasis. Posterior limb of the internal capsule fractional anisotropy showed potential to distinguish those patients with rapid progression. Axial diffusivity significantly increased in this region in a paired t-test analysis of baseline and follow-up diffusion tensor imaging, in keeping with axonal damage. No correlations were noted for the corpus callosum.

**Conclusions:** Posterior limb of the internal capsule fractional anisotropy is a candidate prognostic marker in amyotrophic lateral sclerosis, with potential to identify incident cases with more rapid progression.

time. In 2 cross-sectional studies, greater FA values were noted among those patients with the longest disease durations, with the possibility that absolute FA values might have inherent prognostic value. In a survival analysis using whole CST FA measurement, lower values were a significantly adverse covariate.

This DTI study sought to identify the parts of the CST or CC that might be most sensitive to progression rate across a range of phenotypes (including some cases of PLS) using tract-based spatial statistics (TBSS).

**METHODS**

**PARTICIPANTS AND CLINICAL MEASURES**

Patients were recruited from the Oxford Motor Neuron Disease Care & Research Centre, having been diagnosed as having ALS or PLS by 2 experienced neurologists (M.R.T. and K.T.). Ethical approval for all procedures was obtained (South Central Oxford Ethics Committee reference number: 08/H0605/85).

Patients were clinically examined on the day of MRI and again after an approximate 6-month interval by the same person (M.R.T.). The functional status of all patients was assessed using the revised ALS Functional Rating Scale (ALSFRS-R), in which a lower score reflects greater disability. The difference between the 2 scores for each patient was divided by the exact number of days between the baseline and follow-up assessment to calculate a rate of ALSFRS-R score change, synonymous in this article with progression rate. To investigate longitudinal changes of white matter microstructural integrity, MRI was repeated on the day of the 6-month follow-up assessment.

There was some overlap in the patients with ALS (but not PLS) in a previously published DTI study from our group.

**IMAGE ACQUISITION AND ANALYSIS**

Whole-brain DTI images were acquired with a 3-T Siemens Trio MR scanner (Siemens) with a 12-channel head coil using an echoplanar imaging sequence (60 isotropic directions; b value = 1000 seconds/mm²; echo time/repetition time = 94 ms/10 000 ms; 2 × 2 × 2 mm³ voxel size; 65 slices). In addition, 4 images without diffusion weighting were acquired. Furthermore, a field map was acquired using a gradient echo imaging sequence (2 × 2 × 2 mm³ voxel size; 65 slices; echo time = 7.65 ms/653 ms) to account for distortions caused by field inhomogeneities.

All images were analyzed using the Oxford Centre for Functional Magnetic Resonance of the Brain software library tools. All scans were corrected for head motion and eddy currents and then brain extracted to remove any nonbrain voxels. To correct for B0 inhomogeneities and unwarp scans, field map correction was performed with FUGUE software. Fractional anisotropy, mean diffusivity (MD), L1, L2, and L3 maps were created using DTIFIT software by applying a diffusion tensor model to each voxel. Individual FA images of all subjects were nonlinearly registered to a standard FA template (http://www.fmrib.ox.ac.uk/fsi/data/FMRIB58_FA), and then averaged to create a study-specific template to which each subject’s FA map was then nonlinearly registered. The same transformation that was used to register the individual FA images to the study-specific template was subsequently applied to register the individual MD, L1, L2, and L3 images.

**RESULTS**

Twenty-four patients were recruited, 21 with ALS and 3 with PLS. Demographic and clinical parameters are shown in the Table. Mean (SD) age at baseline scan was 60 (12) years (range, 39-83 years). Mean (SD) disease duration (symptom onset to baseline scan) was 65 (54) months (range, 10-247 months). Mean (SD) ALSFRS-R score at baseline was 34 (4) (range, 10-247 months). Mean (SD) ALSFRS-R score at baseline was 34 (4) (range, 26-43), and a mean (SD) change in score of 4 (6) (range, 0-25). The mean (SD) assessment interval was 193 (19) days (range, 154-222 days). There was no significant difference in progression rate for bulbar-onset vs limb-onset patients in our cohort.

**TBSS ROI ANALYSIS**

Tract-based spatial statistics ROI analysis included the following measures and outcomes.

1. Baseline DTI measures vs baseline ALSFRS-R score: No significant correlation was found for either ROI.
2. Baseline DTI measures vs baseline disease duration: A positive correlation with the eigenvalue L3 was seen in the right upper CST.
3. Baseline DTI measures vs rate of progression: A region was identified spanning the PLIC bilaterally in which

**REGIONS OF INTEREST**

The Juellist Histological Atlas was used to produce masks of the left and right CST in Montreal Neurological Institute standard space (threshold, 25). The CC mask was taken from the Johns Hopkins University ICBM-DTI-81 White-Matter Labels Atlas.
there was significant correlation between baseline FA and the rate of ALSFRS-R score change ($P < .05$, FWE and age corrected). With correction for disease duration, correlation within the left PLIC remained significant (Figure 1). Positive correlations were also found for the eigenvalue L3 and MD in the left CST, which persisted with the addition of correction for disease duration (not shown).

No significant correlations were observed between DTI measures and rate of progression for the CC ROI.

**TBSS LONGITUDINAL ANALYSIS**

Nineteen of the 24 patients had a usable second MRI for additional longitudinal analysis of DTI measures (5 data sets had to be discarded owing to spike artifacts). Paired $t$ test analysis revealed higher axial diffusivity (eigenvalue L1) at follow up in the region of the left PLIC (Figure 2). There was no significant change in the other eigenvalues, FA, or MD.

**COMMENT**

This study demonstrated that FA is correlated with progression rate within a specific region of the CST spanning the PLIC, and across a range of phenotypes including patients with PLS and some patients with ALS with few UMN signs clinically. In a longitudinal analysis of interval scans, there was corroborative evidence of axonal damage (namely increased axial diffusivity) in this region.

Only 4 patients lay above the median rate of progression in our study, with a marked spread of FA values in those below the median. Therefore, the prognostic value of PLIC FA may be limited to identifying rapidly progressing cases below a cutoff value ($<0.62$ in this study), similar to the observation in a previous survival analysis that used whole CST FA as a covariate. Nonetheless, early identification of such individuals would have clear value in care planning and potentially also stratification of patients in therapeutic trials.

**CST FA AND DISABILITY IN ALS**

Multiple cross-sectional studies using DTI in ALS have noted FA decreases within 1 or more CSTs compared with healthy control subjects, some noting correlations with disability at the time of the scan. However, a volumetric DTI analysis of the CST did not reveal any regional correlations with absolute ALSFRS-R values (or other clinical measures). In a small longitudinal study involving 7 patients with ALS with prominent UMN signs (ie, El Escorial probable and definite categories), a correlation was noted between CST FA and absolute ALSFRS-R scores at the time of the scans ($R^2 = 0.64$), but progression rate was not studied.

**PLIC IN ALS**

Involvement of the PLIC was specifically noted in post-mortem study of cerebral white matter tract degenera-

---

### Table. Clinical and Demographic Patient Features

<table>
<thead>
<tr>
<th>Patient Sex/ Age at MRI, y</th>
<th>Diagnosis</th>
<th>Site of Onset</th>
<th>EE Category</th>
<th>Disease Duration, mo</th>
<th>Baseline ALSFRS-R Score</th>
<th>Change in ALSFRS-R Score</th>
<th>Assessment Interval, d</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/69</td>
<td>ALS</td>
<td>R UL</td>
<td>Possible</td>
<td>32</td>
<td>33</td>
<td>1</td>
<td>189</td>
</tr>
<tr>
<td>F/67</td>
<td>ALS</td>
<td>B0</td>
<td>Possible</td>
<td>62</td>
<td>33</td>
<td>4</td>
<td>191</td>
</tr>
<tr>
<td>M/76</td>
<td>ALS</td>
<td>B0</td>
<td>Possible</td>
<td>43</td>
<td>33</td>
<td>4</td>
<td>210</td>
</tr>
<tr>
<td>F/54</td>
<td>ALS</td>
<td>R LL</td>
<td>Definite</td>
<td>38</td>
<td>36</td>
<td>4</td>
<td>176</td>
</tr>
<tr>
<td>F/47</td>
<td>ALS</td>
<td>R LL</td>
<td>Definite</td>
<td>122</td>
<td>34</td>
<td>2</td>
<td>217</td>
</tr>
<tr>
<td>M/53</td>
<td>ALS</td>
<td>R UL</td>
<td>Probable</td>
<td>24</td>
<td>26</td>
<td>3</td>
<td>219</td>
</tr>
<tr>
<td>M/69</td>
<td>ALS</td>
<td>L UL</td>
<td>Possible</td>
<td>33</td>
<td>39</td>
<td>5</td>
<td>161</td>
</tr>
<tr>
<td>M/67</td>
<td>ALS</td>
<td>B0</td>
<td>Definite</td>
<td>10</td>
<td>32</td>
<td>25</td>
<td>154</td>
</tr>
<tr>
<td>F/48</td>
<td>ALS</td>
<td>R UL</td>
<td>Possible</td>
<td>73</td>
<td>33</td>
<td>1</td>
<td>196</td>
</tr>
<tr>
<td>F/55</td>
<td>ALS</td>
<td>L LL</td>
<td>Probable</td>
<td>78</td>
<td>37</td>
<td>1</td>
<td>196</td>
</tr>
<tr>
<td>M/59</td>
<td>ALS</td>
<td>L LL</td>
<td>Probable</td>
<td>21</td>
<td>37</td>
<td>3</td>
<td>191</td>
</tr>
<tr>
<td>M/69</td>
<td>ALS</td>
<td>R UL</td>
<td>Possible</td>
<td>78</td>
<td>34</td>
<td>4</td>
<td>215</td>
</tr>
<tr>
<td>F/55</td>
<td>ALS</td>
<td>L LL</td>
<td>Probable</td>
<td>28</td>
<td>35</td>
<td>13</td>
<td>189</td>
</tr>
<tr>
<td>M/39</td>
<td>ALS</td>
<td>L UL</td>
<td>Definite</td>
<td>22</td>
<td>35</td>
<td>3</td>
<td>168</td>
</tr>
<tr>
<td>M/63</td>
<td>ALS</td>
<td>L LL</td>
<td>Suspected*</td>
<td>75</td>
<td>30</td>
<td>1</td>
<td>209</td>
</tr>
<tr>
<td>M/41</td>
<td>ALS</td>
<td>R UL</td>
<td>Definite</td>
<td>79</td>
<td>36</td>
<td>1</td>
<td>191</td>
</tr>
<tr>
<td>M/60</td>
<td>ALS</td>
<td>R UL</td>
<td>Possible</td>
<td>121</td>
<td>28</td>
<td>1</td>
<td>210</td>
</tr>
<tr>
<td>M/83</td>
<td>ALS</td>
<td>R UL</td>
<td>Possible</td>
<td>107</td>
<td>32</td>
<td>1</td>
<td>182</td>
</tr>
<tr>
<td>M/50</td>
<td>ALS</td>
<td>B0</td>
<td>Probable</td>
<td>13</td>
<td>36</td>
<td>11</td>
<td>161</td>
</tr>
<tr>
<td>M/65</td>
<td>ALS</td>
<td>B0</td>
<td>Possible</td>
<td>29</td>
<td>43</td>
<td>0</td>
<td>208</td>
</tr>
<tr>
<td>F/46</td>
<td>ALS</td>
<td>R LL</td>
<td>Definite</td>
<td>20</td>
<td>32</td>
<td>14</td>
<td>222</td>
</tr>
<tr>
<td>F/76</td>
<td>PLS</td>
<td>B0</td>
<td>Possible</td>
<td>143</td>
<td>32</td>
<td>2</td>
<td>175</td>
</tr>
<tr>
<td>F/64</td>
<td>PLS</td>
<td>L LL</td>
<td>Possible</td>
<td>247</td>
<td>29</td>
<td>1</td>
<td>194</td>
</tr>
<tr>
<td>F/76</td>
<td>PLS</td>
<td>Legs</td>
<td>Possible</td>
<td>56</td>
<td>37</td>
<td>2</td>
<td>196</td>
</tr>
</tbody>
</table>

Abbreviations: ALS, amyotrophic lateral sclerosis; BO, bulbar onset; EE, El Escorial; F, female; FRS, Functional Rating Scale; L, left; LL, lower limb; M, male; MRI, magnetic resonance imaging; PLS, primary lateral sclerosis; R, right; UL, upper limb.

\*Evolved to possible.
tion in ALS. Hyperintensities within the PLICs were noted on one of the first MRI studies in ALS, and specifically on proton-density images. Intensity changes within this region are a common observation on routine clinical MRI studies during the diagnostic workup of patients with ALS, but they lack sensitivity.

Tractography studies have shown that the PLIC maps to motor and premotor cortices, which is entirely in keeping with the burden of cerebral pathology in ALS. Posterior limb of the internal capsule FA has been previously linked broadly to clinical disease burden in ROI-based DTI analysis and highlighted in spectroscopy studies. Posterior limb of the internal capsule involvement was also a consistent feature in the meta-analysis of 8 DTI studies in ALS. An attempt to assess corticobulbar pathway involvement using DTI used a region including the PLIC and was shown to have lower FA values in bulbar-onset patients. We did not note a significant difference in our cohort for progression rate and site of onset, although this may simply reflect the small sample size.

Reduced PLIC FA was noted in a DTI study of healthy presymptomatic subjects at risk for ALS through autosomal dominant mutations of the superoxide dismutase-1 (SOD1) gene, suggesting this region may even have sensitivity to the preclinical pathologic changes in ALS.

**DISEASE DURATION AND APPARENT LATERALIZATION**

Our patient group contained patients of relatively long disease duration. By definition, such patients have a slower rate of progression. Curve estimation for disease duration plotted against progression rate confirmed an inverse relationship in our cohort, although importantly
there was no correlation between baseline ALSFRS-R score and disease duration (data not shown). Patients with more benign disease tend to present much later to specialist clinics,38 leading to an inherent bias in many ALS research studies whereby the cases with the shorter disease durations are invariably also the most rapidly progressive. Thus, disease duration must always be considered as a potential confound.

Prior to the inclusion of disease duration as an additional covariate, the area of significant FA reduction was bilateral in our cohort but became restricted to only the left CST thereafter. The longitudinal DTI changes were also restricted to the left CST. There was no obvious bias in the laterization of initial limb symptoms. Concordance has been observed for handedness and site of first symptoms in patients with upper limb–onset ALS,39 but less than half of our patients (10 of 24) had right-sided limb onset of symptoms and fewer (7 of 24) had upper limb onset in a group of nearly all right-handed patients and control subjects. Other DTI studies in ALS have reported apparent laterization of CST involvement to the right upper CST.13,40 There is also an under-recognized post mortem observation of potential relevance that the human CST is asymmetric in 75% of individuals, with 75% of these cases having a larger decussation to the right-sided cord CST.41

However, FA changes have been observed in the PLIC on both affected and nonaffected sides according to disease burden,32 and they appear bilaterally in DTI meta-analysis.35 Correlations of CST FA were similar for both the left and right sides in our data. Therefore, we remain cautious in the interpretation of any apparent lateralization of PLIC (or wider CST) vulnerability but suggest that the specific longitudinal study of patients with ALS with strongly lateralized signs may be valuable in clarifying this issue.

FA AS A PROGNOSTIC VS MONITORING BIOMARKER

In most clinical studies in ALS, assessments will inevitably be made in groups of patients with variable progression slopes, disease duration, and disability at the time of study, as well as differing stages in terms of their total disease course (see Figure 1 in study by Grosskreutz et al42). For these reasons alone, it is perhaps not surprising that some DTI studies have failed to demonstrate significant reductions in FA longitudinally,43 including this study. Potential issues of heterogeneity and method differences notwithstanding, 2 studies (1 from our group) have however specifically noted paradoxically greater FA values in those patients with longer disease duration (ie, slower progression rates).6,9 We previously speculated that “the CST may be more resistant to disease-related damage in some patients with ALS, or such individuals have a higher baseline FA.”6 This study may lend further support to this concept (ie, FA may better reflect prognosis rather than longitudinal change).

The lack of correlation of any callosal DTI measures with progression rate may reflect the more consistent and perhaps very early involvement of this tract in ALS pathogenesis.

Post hoc, we considered the potential confounding effects of variable UMN involvement in the patients, using a pathologic reflex sum score gathered as part of the clinical assessment (see study by Filippini et al). High UMN scores were significantly correlated with lower FA values in the CSTs (data not shown), in keeping with previous observations.6,43 However, as a general observation, patients with UMN-predominant ALS and those with PLS (UMN only, by definition) are recognized to show consistently slower rates of progression.44,45 Thus, UMN involvement potentially antagonizes the relationship between FA and progression rate. However, after adding the UMN score as an additional covariate of no interest, we still observed a significant negative correlation between CST FA and progression rate (data not shown), suggesting that FA is an independent prognostic factor.

As a wider point, we encourage reanalysis of imaging (and other biomarker) data sets using overall survival once this is known for the entire cohort. This will allow the disease stage at which investigation was performed to be used as a covariate, which may help to untangle prognostic hetero-
CONCLUSION

Fractional anisotropy within the PLIC appears to have promising potential in identifying those cases of ALS associated with rapid progression. Further survival analyses are needed, ideally capturing the much more elusive short duration–slow progression patients. For the broader aim of the development of candidate neuroimaging surrogate markers that provide clear benefit over simpler and cheaper clinical measures such as the ALSFRS-R score, it seems likely that it will need to involve a multimodal approach with functional as well as structural measures, possibly with additional cerebrospinal fluid markers. The addition of a baseline and interval multimodal MRI to the protocol of future therapeutic trials seems a logical and imperative step toward this aim. This will require standardization and harmonization of MRI acquisition and analysis across international sites, an early framework for which has been established.

Accepted for Publication: April 4, 2012.
Published Online: August 20, 2012. doi:10.1001/archneurol.2012.1122

Correspondence: Martin Turner, PhD, University of Oxford Nuffield Department of Clinical Neurosciences, West Wing Level 3, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom (martin.turner@ndcn.ox.ac.uk).

Author Contributions: Study concept and design: Talbot and Turner. Acquisition of data: Knight and Turner. Analysis and interpretation of data: Menke, Abraham, Thiel, Filipponi, and Turner. Drafting of the manuscript: Menke, Abraham, Thiel, Filipponi, and Turner. Critical revision of the manuscript for important intellectual content: Thiel, Filipponi, Knight, Talbot, and Turner. Statistical analysis: Menke, Abraham, Filipponi, and Turner. Obtained funding: Turner. Administrative, technical, and material support: Talbot and Turner. Study supervision: Menke, Talbot, and Turner.

Conflict of Interest Disclosures: Dr Menke’s work is funded by the Parkinson’s Disease Society of the United Kingdom. Dr Turner’s work is funded by Lady Edith Wolfson Fellowship grant G0701923 from the Medical Research Council/Motor Neurone Disease Association UK.

Funding/Support: The Oxford Motor Neuron Disease Care & Research Centre receives funding from the Motor Neurone Disease Association UK Care Centre Program.

Additional Contributions: We are indebted to Research Assistant Melanie Lord, BSc; Center Coordinator/Specialist Nurse Rachael Marsden, MSc; and our patients with amyotrophic lateral sclerosis and their caregivers.

REFERENCES